MQX‐503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial

Naomi Rothfield, Lee Shapiro, David Fiorentino, Lorinda Chung, Christopher Denton, Ariane Herrick, Murray Baron, Joseph Shanahan, Vivien Hsu, Jill Belch, Virginia Steen, Agneta Scheja, Richard Martin, Edwin Smith, Maureen Mayes, Robert Simms, Janet Pope, Bashar Kahaleh, Mary Ellen Csuka, Barry GruberDavid Collier, Nadera Sweiss, Sangeeta Sule, Paul Emery, Fredrick M. Wigey

Research output: Contribution to journalBook/Film/Article review

Abstract

Objective Raynaud's phenomenon (RP) affects 3–9% of the general population and >90% of patients with systemic sclerosis. Nitrates are often prescribed for the treatment of RP, but currently available formulations are limited by side effects, particularly headaches, dizziness, and skin irritation. The purpose of this study was to evaluate the tolerability and efficacy of a novel formulation of topical nitroglycerin, MQX‐503, in the treatment of RP in an ambulatory setting. Methods We conducted a multicenter, randomized, placebo‐controlled study with a 2‐week single‐blind run‐in period to determine baseline severity, followed by a 4‐week double‐blind treatment phase. Two hundred nineteen adult patients with a clinical diagnosis of primary or secondary RP received 0.9% MQX‐503 gel or matching placebo during the treatment period. Gel was applied immediately before or within 5 minutes of the beginning of an episode of RP (maximum of 4 applications daily). End points included the change in the mean Raynaud's Condition Score (RCS; scale 0–10), the frequency and duration of episodes, and subjective assessments at the target week (the week during the treatment phase that most closely matched the run‐in period in terms of ambient temperature) compared with baseline. Results The mean (%) change in the RCS at the target week compared with baseline was significantly greater in the MQX‐503 group (0.48 [14.3%]) than that in the placebo group (0.04 [1.3%]; P = 0.04). Changes in the frequency and duration of RP episodes and subjective assessments were not statistically different between the groups. MQX‐503 had a side effect profile similar to that of placebo. Conclusion MQX‐503 is well tolerated and more effective than placebo for the treatment of RP.
Original languageEnglish
Pages (from-to)S821-S821
Number of pages1
JournalArthritis & Rheumatism
Volume58
Issue number9
Publication statusPublished - Sep 2008

Cite this

Rothfield, N., Shapiro, L., Fiorentino, D., Chung, L., Denton, C., Herrick, A., Baron, M., Shanahan, J., Hsu, V., Belch, J., Steen, V., Scheja, A., Martin, R., Smith, E., Mayes, M., Simms, R., Pope, J., Kahaleh, B., Csuka, M. E., ... Wigey, F. M. (2008). MQX‐503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial. Arthritis & Rheumatism, 58(9), S821-S821.